Lexaria Bioscience Corp.

Snapshot

Lexaria is a tiny preclinical biotech testing its DehydraTECH drug-delivery platform on GLP-1 compounds. FY2025 revenue grew 52% to $706K, but the company lost $11.9M, roughly 17 times revenue, and burned $10.5M in cash.

What's Happening Right Now

• Thu 15th Oct '26 · Animal study: On Oct 15, 2026, Lexaria reported preclinical results from animal study GLP-1-A26-1, highlighting a 566% improvement in brain absorption for a DehydraTECH-CBD formulation and filing 3 new patent applications; semaglutide brain-tissue results were non-reportable.
• Tue 13th Oct '26 · Dilution filing: On Oct 13, 2026, Lexaria filed a 424B3 prospectus (following an Oct 2 S-3) registering resale of 923,827 shares tied to September 2026 warrant inducement warrants, adding a dilution overhang equal to roughly 30-44% of shares outstanding.
• Fri 2nd Oct '26 · Registration: Registered additional securities for sale on Form S-1.
• Fri 2nd Oct '26 · Registration: Registered 924K shares for sale on Form S-3.
• Wed 9th Sep '26 · Offering: Raised $5.90M in gross proceeds through an offering, with warrants over 924K shares.
• Mon 17th Aug '26 · Nasdaq compliance: On Aug 17, 2026, Nasdaq confirmed Lexaria regained compliance with the minimum bid price rule, cancelling its delisting hearing and removing the delisting overhang.
• Thu 13th Aug '26 · Partnership: On Aug 13, 2026, Lexaria entered a Material Transfer Agreement with Hong Kong-listed PegBio to test DehydraTECH on a proprietary GLP-1 molecule for diabetes and weight loss.
• Thu 30th Jul '26 · Reverse split: Lexaria's 1-for-15 reverse stock split took effect Aug 3, 2026, cutting shares outstanding from about 24.8 million to 1.65 million to regain Nasdaq's $1.00 minimum bid price compliance.